Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases - Cheng, D; Kochar, B D; Cai, T (Clin Gastroenterol Hepatol, 2022)
et al.